Regulatory Filing Details
Regulation Reference: Regulation 30 of SEBI (LODR) Regulations, 2015
Key Announcement: Partnership and Product Launch
RPG Life Sciences (RPG LS) has entered into a partnership with Archerchem Healthcare Limited to launch Naprosyn ES (Naproxen and Esomeprazole combination) for the first time in India. This partnership strengthens the existing business relationship between the two companies.
Product Details
- Product Name: Naprosyn ES
- Composition: Combination of Naproxen (anti-inflammatory) and Esomeprazole (gastroprotective agent)
- Purpose: Designed to deliver effective anti-inflammatory solution along with gastroprotection
- Development: The combination was co-developed by Archerchem Healthcare along with its development partner
- Availability: The product is available pan-India
Commercial Arrangements
- Marketing Rights: RPG Life Sciences will exclusively market and distribute Naprosyn ES across India
- Supply Arrangement: Archerchem will serve as the exclusive supplier of the product
Strategic Rationale and Market Positioning
The product addresses a significant unmet need in patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation is expected to:
- Improve patient compliance
- Enable safer long-term pain management
- Benefit elderly and gastro-sensitive populations
RPG Life Sciences will leverage the strong legacy and brand recall of the Naprosyn brand and utilize its:
- Robust reach to a wide spectrum of doctors, including super-specialists
- Pan-India distribution network
The launch aligns with RPG Life Sciences' continued focus on building a differentiated portfolio in chronic therapy segments.
Management Commentary
Ashok Nair, Managing Director, RPG Life Sciences: "At RPG Life Sciences, innovation is rooted in patient centricity. Naprosyn ES is an example of our strong R&D-driven approach to differentiated products, and the long-standing trust that doctors and patients place in the Naprosyn brand."
Anil Dhedia, Chairman & Managing Director, Archerchem Healthcare: "This partnership exemplifies Archerchem's core strength in developing complex differential formulations. Through our partnership with RPG Life Sciences, a leading pharmaceutical company with strong presence in multiple chronic and acute therapies including in pain management segment, we are proud to deliver incremental innovation that enhances medication adherence and brings meaningful benefit to patients across India."
Company Background Information
RPG Life Sciences Ltd: An integrated research-based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality and affordable medicines.
Archerchem Healthcare Limited: An Indian pharmaceutical company with global footprint, focused on accessibility and affordability through generics. Headquartered in Mumbai, India, with expertise in complex formulations and therapy-agnostic portfolio of life-saving and critical care drugs.